Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Julphar
Boehringer Ingelheim
Covington
Dow
Farmers Insurance
Harvard Business School
Moodys
US Department of Justice

Generated: January 21, 2019

DrugPatentWatch Database Preview

MOZOBIL Drug Profile

« Back to Dashboard

Which patents cover Mozobil, and when can generic versions of Mozobil launch?

Mozobil is a drug marketed by Genzyme and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-two patent family members in twenty-nine countries.

The generic ingredient in MOZOBIL is plerixafor. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the plerixafor profile page.

Drug patent expirations by year for MOZOBIL
Pharmacology for MOZOBIL
Synonyms for MOZOBIL
078P461
1-({4-[(1,4,8,11-tetraazacyclotetradecan-1-yl)methyl]phenyl}methyl)-1,4,8,11-tetraazacyclotetradecane
1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane
1-{[4-(1,4,8,11-tetraazacyclotetradecan-1-ylmethyl)phenyl]methyl}-1,4,8,11-tetraazacyclotetradecane
1,1'-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane
1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]
1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA)
1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin( HHA)
1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin(HHA)
1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}
1,1''''-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}
1,1'[1,4-phenylene-bis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
1,4-Bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene
1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane
1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane(8HBr.2H2O)
11-{4-[4,8, 11-1,4,8,11tetraaza-cyclotetradec-1-ylmethyl]-benzyl}-1,4,8,11tetraaza-cyclotetradecane-1,4,8-tricarboxylic acid tri-tert-butyl ester
11''''-xylyl bis-1,4,8,11-tetraazacyclotetradecane
110078-46-1
155148-31-5
3B1-000393
4CA-1029
A25446
A809618
AB0009909
AB01566900_01
AB1008451
AC-26837
AC1L22ET
AJ-81365
AK-41732
AKOS005266706
Amd 3100
AMD-3100
AMD3100
AMD3100 octahydrochloride
AN-436
ANW-73610
AOB5591
BC623053
BCPP000104
BDBM50035696
bicyclam JM-2987
BRD-K33240821-367-01-8
C28H54N8
CHEBI:125354
CHEMBL18442
CS-0451
CTK8C4952
D08971
D0L5RW
DB06809
FT-0660392
GNA & AMD-3100
GTPL844
HE070541
HE295036
HHA & AMD-3100
HY-10046
I14-9461
J-503718
JM 2987
JM 3100
JM 3100, AMD3100
JM-3100
JM3100
KS-00000OBY
L000104
LS-187299
MFCD05662218
MolPort-009-019-417
Mozobil (TN)
NCGC00165722-01
NCGC00165722-02
Plerixafor
plerixafor (amd3100)
Plerixafor (INN/USAN)
Plerixafor (JAN/USAN/INN)
Plerixafor 8HCl
Plerixafor hcl
Plerixafor hydrochloride
Plerixafor(AMD3100)
RL00426
S-7677
s8030
S915P5499N
SC-21932
SCHEMBL19038
SDZ SID 791
SID791
SR-01000941593
SR-01000941593-1
ST2414835
TC-162355
UNII-S915P5499N
YIQPUIGJQJDJOS-UHFFFAOYSA-N
Z2196779619
ZINC22443609

US Patents and Regulatory Information for MOZOBIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for MOZOBIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for MOZOBIL
Drugname Dosage Strength RLD Date
➤ Subscribe Injection 24 mg/1.2 mL vials (20 mg/mL) ➤ Subscribe ➤ Try a Free Trial

Supplementary Protection Certificates for MOZOBIL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB10/004 United Kingdom ➤ Try a Free Trial PRODUCT NAME: PLERIXAFOR IN ALL FORMS PROTECTED BY THE BASIC PATENT; REGISTERED: UK EU/1/09/537/001 20090731; REASON FOR LAPSE: SURRENDERED
00425 Netherlands ➤ Try a Free Trial PRODUCT NAME: PLERIXAFOR, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH ZUURADDITIE ZOUT OF METAALCOMPLEX; REGISTRATION NO/DATE: EU/1/09/537/001 20090731
00537 Netherlands ➤ Try a Free Trial PRODUCT NAME: PLERIXAFOR IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VORM; REGISTRATION NO/DATE: EU/1/09/537/001 20090731
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Argus Health
Baxter
US Department of Justice
Citi
Teva
Daiichi Sankyo
AstraZeneca
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.